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Abstract
On December 3–4 2012, the World Health Organization convened a meeting of influenza vaccine 
effectiveness (VE) experts from over 25 countries in Geneva, Switzerland, to review recent 
developments in the global influenza vaccine landscape and evaluate approaches to determining 
the effectiveness of influenza vaccine products among target populations. Vaccine manufacturers 
from Thailand, Vietnam, India, and Brazil shared recent advances illustrating the expansion of 
influenza vaccine production worldwide. Randomized controlled trials are underway in several 
low and middle-income countries including India, Thailand, Bangladesh, and South Africa, to fill 
knowledge gaps in target populations such as children and pregnant women. National and 
international networks in the United States, Canada, Europe, Latin America and Australia are 
conducting multi-site observational studies with shared methodologies to generate national 
influenza VE estimates and pool data for regional estimates. Standardized VE estimation methods 
are key to generating point estimates that are comparable internationally and across different 
settings.
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1. Introduction
On December 3–4 2012, the World Health Organization (WHO) convened a meeting of 
experts on studies of influenza vaccine effectiveness from over 25 countries in Geneva, 
Switzerland, to review developments in the global landscape of influenza vaccines and in 
particular, the measurement of the effectiveness of different influenza vaccines. In late 2012, 
WHO released a position paper on influenza vaccination, stating that, for countries 
considering the initiation or expansion of seasonal influenza vaccine programs, pregnant 
women should have the highest priority. WHO also stated that additional risk groups to be 
considered for vaccination, in no particular order of priority, are: children aged 6–59 months, 
the elderly, individuals with specific chronic medical conditions, and health-care workers 
[1]. A further development is the increasing number of manufacturers that are developing 
and producing influenza vaccines – expanding global manufacturing capacity that will make 
vaccines increasingly available and aid pandemic preparedness efforts [2]. The range of 
influenza vaccine products has also diversified to include additional inactivated vaccines 
(e.g., adjuvanted, high-dose formulations, intradermal, cell-culture-based vaccines), live 
attenuated vaccines, and recombinant protein vaccines, and the recent development of 
quadrivalent formulations. These newly licensed vaccines may provide increased clinical 
protection in groups that tend to respond poorly such as young children and the elderly. 
Further, in the last 5–10 years, the burden of seasonal influenza has been increasingly 
documented in settings where data had previously been limited [3–5]. This expanding 
evidence base is particularly valuable in low- and middle-income settings, where disease 
burden may be high and where risk factors for severe disease may differ from high-income 
locations.
Efforts to increase worldwide influenza vaccine availability have highlighted the need for 
ongoing data on the effectiveness of influenza vaccines in settings where influenza 
vaccination programs are conducted. In addition, measuring the relative and absolute 
effectiveness of newly licensed products by age group and setting, and the effectiveness of 
influenza vaccines newly introduced into a country’s immunization programs will be 
necessary data for evaluating the value of influenza vaccines in the next decade. Recent 
meta-analyses have highlighted the uncertainty of the protection afforded by traditional 
vaccines and have challenged the evidence for significant protection of the elderly [6,7]. 
Furthermore, certain knowledge gaps remain for current vaccines, including the relative 
effectiveness of live-attenuated and adjuvanted vaccines in young children versus older 
children and the availability of robust estimates of vaccine effectiveness (VE) among 
children with high-risk medical conditions as well as pregnant women and their infants. 
Multiple challenges in addressing these gaps include the inherent antigenic variability of the 
circulating influenza viruses as well as how best to classify “matched” and “mismatched” 
virus strains, and the differences in influenza seasonality between temperate and tropical 
locations.
These recent developments have generated a need for an international collaboration to 
review methods to measure vaccine effectiveness and to identify opportunities for 
international data sharing to provide the best informed conclusions. The objectives of the 
meeting were: to provide an update on advances in influenza vaccination in low- and 
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middle-income settings; to summarize global efforts to better measure influenza vaccine 
effectiveness and efficacy; to identify best practices and determine critical knowledge gaps; 
to discuss opportunities for global collaboration such as for pooling of observational data; 
and to identify specific challenges in communicating data. This report provides an overview 
of the findings of this meeting, as well as several key areas of discussion.
2. Expanded global picture of influenza vaccination
2.1. Influenza vaccine production in middle-income countries
Vaccine manufacturers from Thailand, Vietnam, India, and Brazil shared recent advances 
that illustrated the expanding landscape for influenza vaccines production worldwide. In 
Thailand, the Government Pharmaceutical Organization (GPO) presented work to develop 
and produce an inactivated influenza vaccine (IIV) and a live-attenuated influenza vaccine 
(LAIV) for local use among recommended target groups. Their aims are to develop national 
capacity for seasonal vaccination with IIV and additionally produce a small volume of 
seasonal LAIV annually that could be scaled up rapidly in the case of a pandemic. 
VABIOTECH (Vietnam) influenza vaccine development is guided by similar priorities of 
protecting the population against potential pandemic influenza viruses such as influenza 
A(H5N1) and other avian influenza strains. A cell culture-derived inactivated H5N1 vaccine 
has completed Phase IIb trials, while production of seasonal influenza vaccines are being 
explored for 2014–2015. The Serum Institute of India (SII) developed a monovalent 
influenza A(H1N1)pdm09 LAIV that was licensed in India in July 2010, and their trivalent 
LAIV formulations have completed Phase I and II clinical trials for use in children (2–17 
years) and adults. At time of presentation, the trivalent LAIV was under review for licensure 
by the national regulatory agency (Drug Controller General of India (DCGI).1 In Brazil, 
where influenza vaccines for persons over 65 years and children under 5 years are provided 
by the federal government, Butantan produces southern hemisphere formulations of IIV, and 
it is currently exploring several options for low-cost adjuvants to improve immune response.
2.2. Vaccine efficacy research in low- and middle-income country settings
A systematic review of influenza VE studies from low- and middle-income countries 
published to date showed limited information on vaccine efficacy and effectiveness. Of the 
available published studies from lower-resource settings, a large proportion did not describe 
their methods for randomization and blinding. Insufficient randomization and blinding can 
introduce bias during ascertainment of outcomes, since study participants and/or 
investigators may be aware of which vaccines have been administered, thereby 
systematically altering who is tested for influenza. High-quality data from these settings are 
critical, since the effectiveness of influenza vaccines in a given setting may be influenced by 
a range of factors, including the prevalence of comorbidities, influenza seasonality and 
vaccine formulation used. In many low-to middle-income settings, age distribution and 
health conditions such as HIV, tuberculosis, malnutrition, malaria and other factors will 
1The Serum Institute of India’s trivalent live attenuated influenza vaccine was licensed by the Drug Controller General of India in 
2013.
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differ from that of the United States (US) and other settings that have traditionally conducted 
studies of influenza vaccine efficacy.
Although published literature is limited, summaries of randomized controlled trials in 
several low and middle-income countries were presented from researchers in India, 
Thailand, Bangladesh, and South Africa. In India, a multi-year household-randomized study 
began in 2009 to estimate the direct and indirect effects of vaccinating children 6 months to 
10 years with IIV in three villages near Delhi. Also in India, a seasonal trivalent LAIV is in 
the process of obtaining licensure1, and a new Phase IV study is being designed to evaluate 
the effectiveness of locally produced LAIV versus placebo or trivalent IIV among children 
2–10 years of age once that vaccine is licensed. In Thailand, clinical research activities for 
influenza vaccines include safety and immunogenicity studies of monovalent 
A(H1N1)pdm09 IIV and avian A(H5N2) IIV as well as planning activities for seasonal IIV 
and LAIV evaluation, with clinical trials anticipated to start in 2014–2015. In Bangladesh, a 
maternal immunization trial found a VE of 63% of IIV administered to pregnant women in 
preventing lab-confirmed clinical influenza among infants through 24 weeks, as well as a 
29% reduction in all-cause febrile illness in this group [8]. Additional ongoing studies 
include a randomized controlled trial of quadrivalent IIV in children 12–35 months of age, a 
probe study to quantify the effect of trivalent IIV on all-cause pneumonia, and Phase II/III 
trials of trivalent LAIV in children less than 5 years of age. In South Africa, the “SA Mat-
Flu Study” was initiated in 2011 to determine the immunogenicity of IIV among HIV-
infected and uninfected pregnant women, and to calculate the efficacy of IIV vaccination 
against influenza in their vaccine-exposed infants (up to 24 weeks of age). Initial results 
indicate only modest immunogenicity in HIV-positive pregnant women, which may suggest 
less passive transfer of antibody and decreased clinical effectiveness of IIV in newborns of 
HIV-infected women.
2.3. Vaccine effectiveness networks
A number of national and international efforts have also been established to generate pooled 
VE estimates. In the US, the US Flu VE Network has generated annual estimates of 
influenza VE through a case-control design using influenza-positive cases and influenza-
negative controls (“test-negative” design, or TND) at four to five sites using a case definition 
of medically attended acute respiratory infection (MAARI). In Europe, the I-MOVE network 
(Monitoring Influenza Vaccine Effectiveness in Europe), established in 2007, conducts VE 
research using both case-control and cohort-based approaches at 15 sites across the region, 
taking advantage of computerized national registries where feasible. In Latin America, a 
multinational research effort, REVELAC-i (“Red para la Evaluación de la Efectividad de la 
Vacuna en Latino América y el Caribe – influenza”) was initiated in 2011 to evaluate 
influenza VE in children and older adults, initially in four countries. The REVELAC-i 
approach is also based on a test-negative case-control design, using a case definition of 
severe acute respiratory illness (SARI) and building on sentinel surveillance in hospitals. In 
Australia, several networks collect data to generate annual VE estimates, including FluCAN 
among adult inpatient populations, WAIVE among pediatric inpatient and outpatient 
populations, and the VIDRL outpatient influenza surveillance system, all of which utilize a 
test-negative case–control design. In Canada, national VE estimation is integrated with 
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sentinel surveillance activities across five provinces, also utilizing a test-negative case-
control design.
3. Methodological considerations for estimating vaccine effectiveness
As the diversity of manufacturers and vaccine products increase globally, along with 
increased uptake and new global recommendations and the ethical and financial challenges 
of conducting randomized control trials (RCT) to evaluate VE, observational research is a 
valuable tool for monitoring the effectiveness of these vaccines. Moreover, the variability 
and sometimes limited effectiveness of traditional trivalent IIV highlights the importance of 
robust methodological approaches that allow comparison of data among different studies to 
quantify the public health benefit of influenza vaccines under different epidemiological 
settings [7].
3.1. Observational study designs for influenza vaccine effectiveness
Observational estimates of influenza VE are typically conducted in countries where 
influenza vaccination recommendations make RCT difficult to conduct for ethical reasons, 
or to evaluate public health programs due to relative ease, lower cost, and other feasibility 
concerns. In recent years, influenza researchers have increasingly utilized a test-negative 
case–control design for estimating VE, although case–control studies with community 
controls and cohort/screening designs have also been implemented. TNDs enroll laboratory-
confirmed influenza-positive and negative patients meeting a pre-defined case definition 
such as influenza-like illness (ILI) or SARI from the same healthcare facility, to attempt to 
control for healthcare-seeking behaviors. This design may also provide a comparable source 
population in terms of vaccination coverage (typically higher than among the community, 
due to care-seeking behavior). Additionally, existing SARI surveillance networks can serve 
as a platform for TND VE studies, with adaptations to best collect essential data for vaccine 
effectiveness studies–a concept being piloted in several Latin American countries by 
REVELAC-i. One limitation of test-negative case-control VE studies is their potential for 
misclassification of influenza cases with clinical specimens that do not test positive for 
influenza. Despite the diagnostic sensitivity of influenza testing by reverse transcription 
polymerase chain reaction (RT-PCR), delays in care seeking and testing, especially among 
adults and hospitalized individuals of any age can result in low virus yield and 
misclassification of true influenza cases as non-influenza controls. By using eligibility 
criteria that restrict specimen collection to a time window of a few days after onset when 
viral shedding is highest, this reduces the risk of misclassifying cases, although larger 
sample sizes will likely be needed.
3.2. Measures of effect and study outcomes
Understanding the differences in vaccine study designs is important in the interpretation and 
comparing findings among VE studies. In the context of vaccine research, a study can 
measure a vaccine’s efficacy, effectiveness, or impact. “Efficacy” refers specifically to the 
direct effect of vaccine generated from an RCT. “Effectiveness” refers also to a direct effect, 
but is generally calculated in an observational (usually post-marketing) setting. “Impact” 
includes indirect, total, and overall effects, ideally in two populations or a before and after 
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study. “Overall effect” describes the population-level effects of vaccination (among both 
vaccinated and unvaccinated), while “total effect” is the combined (direct and indirect) effect 
among the vaccinated population. For group-randomized study designs, it can be 
challenging to separately define direct and total effects among vaccinated individuals. 
Additionally, if vaccine coverage in study population is high, this can increase indirect 
effects, resulting in an increased total effect seen through a higher VE than in a community 
with lower vaccine coverage.
Highly specific study endpoints with laboratory confirmation of influenza reduce bias in 
vaccine effectiveness estimates. VE estimates for non-specific outcomes, including 
influenza-like illness, pneumonia or all-cause hospitalizations or deaths, will be much lower, 
and are difficult to interpret, especially if co-circulation of other respiratory pathogens such 
as respiratory syncytial virus that may affect one age group more than others. Of particular 
concern for VE estimates among the elderly that use all-cause mortality as an outcome is 
that frail health is linked to both lower vaccine coverage and high mortality in this 
population, resulting in biased estimates of VE – also known as the “healthy vaccinee” 
effect. Before, during and after-season studies with less specific outcomes can be used to 
demonstrate the impact of influenza on pneumonia hospitalizations in a defined population, 
looking at the “ratio-of-ratios”. This method compares the actual and expected vaccination 
coverage among influenza-positive cases both when influenza is and is not circulating, in 
order to identify confounding due to “healthy vaccinee” status. However, this approach is 
computationally intensive, requiring multiple years of data and a larger number of 
observations [9].
Understanding VE against severe outcomes, however, has great value for policy makers as 
the approach measures the potential impact against a serious and costly public health 
problem. Moreover, it is possible that the effectiveness of some vaccines will vary by 
outcome severity, so that measuring the effectiveness of vaccination against one outcome 
will provide an incomplete picture on the value of vaccination. Large sample sizes are 
required to detect influenza-associated pneumonia or other influenza-associated severe 
diseases. Although high-quality data on the effects of different influenza vaccines on severe 
outcomes are needed, there is no clear consensus on best practices for assessing VE for 
severe outcomes.
3.3. Potential sources of bias and confounding
Several important sources of bias should be considered in estimating VE in both 
observational study and RCT settings. First, test-negative studies require a systematic 
approach to laboratory testing with a standard case definition, as clinician selection of 
participants can result in bias if clinicians decide who to test for influenza based on clinical 
suspicion and assumed vaccine status. Additionally, calendar time may act as a confounding 
variable if cases and controls are not selected at the same time or distributed similarly 
throughout the influenza season and if the vaccine coverage changes during the season. This 
effect can be controlled in case–control studies by matching of cases by epidemiological 
week, and by adjusting for time in analyses. Time from vaccination can also act as an effect 
modifier in any VE study, due to potentially decreasing VE as a result of waning immunity 
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and/or virus antigenic drift over time. However, virus antigenic drift may not always be 
accurately measured by the standard HI assay-based definitions of “matched” and 
“mismatched” influenza strains [10]. Although there is no single best way to adjust for all 
sources of bias and confounding, some standard techniques include collecting basic 
information on healthcare-seeking of the source population, careful selection of controls in 
case–control studies, and ensuring that all VE estimates adjust for key confounders. Also 
needed is a continued validation of approaches to classify “matched” and “mismatched” 
viruses.
4. Communication of vaccine effectiveness estimates
Variability in influenza viruses, and therefore in influenza vaccine effectiveness, presents a 
challenge for public health communication for health professionals and lay population. 
Further, even when circulating viruses are well matched to the vaccine, host factors may 
influence VE estimates, resulting in a lower VE. One key message is that although influenza 
VE may not always be satisfactory in different populations, vaccination is still the most 
effective intervention for preventing infection. Evidence from health communication studies 
suggest that perceived risks are more critical than perceived benefits in the decision-making 
process for vaccination [11,12]. Among pregnant women, vaccines lower the likelihood of 
infection and potential progression to severe disease, but influenza may not be perceived as 
severe in this population, who may instead perceive a higher risk from influenza vaccine-
related side effects than from infection [13]. Among a survey of healthcare workers, lack of 
perceived risk and fear of adverse events were also more important reasons than doubts 
about the vaccine’s effectiveness [14].
Vaccine-related public health messages should be directed at healthcare providers in addition 
to target populations, in order to best communicate risks and benefits of influenza vaccines. 
Surveys in Europe, Australia, and the US, of pregnant women and other groups indicate that 
recommendation from health-care providers is an important factor in the decision to be 
vaccinated [15–17].
5. International data pooling
The advantages of VE data-pooling projects include increased statistical power and precision 
for VE analysis, and generalizable results that can be applied across locations. Increased 
statistical power may also result in earlier determination of VE for mid-season estimates, or 
improved subgroup analyses for key research questions and rare outcomes. Pooling data also 
provides opportunities for additional research, such as correlation of VE with new molecular 
markers or phylogenetic findings. In the European I-MOVE network, for example, key 
objectives of data pooling are to improve sample size and generate regional estimates for 
Europe. I-MOVE also has a pilot project underway to estimate VE against influenza 
hospitalizations. This effort combines data from 21 hospitals at four sites and was able to 
generate age group-specific estimates for 2011–2012, showing a decreasing VE with age 
[18].
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However, data pooling introduces a number of scientific and programmatic challenges that 
must also be considered. Pooling data requires the assumption of a single true VE for any 
one product, which may not be the case. One primary concern is the heterogeneity between 
populations in different settings, including healthcare-seeking behavior, age distribution, 
underlying health conditions, available vaccine products (including usage of northern or 
southern vaccine formulations), local epidemiological conditions and other potential sources 
of bias. The I-MOVE data from 2010 to 2011 identified an outlier VE estimate from one 
country, raising a key question for when to exclude certain sources from pooled estimates. 
There are also methodological concerns such as agreeing on a common protocol, ensuring 
compliance with privacy laws, local ethical considerations and optimizing the use of limited 
financial resources. Given the challenges, preliminary data sharing and consensus on the 
scope of any data-pooling project are necessary before full data pooling can take place. 
Other approaches that should be considered as alternatives to international data pooling 
include rapid sharing of early VE results across hemispheres and meta-analysis of existing 
studies using similar designs.
Standardized VE estimation methods will assist in generating point estimates that are 
comparable internationally. Study design that incorporates test-negative controls is a valid 
standard for VE estimation in observational settings, although studies using community 
controls or cohort design can also provide valuable VE data. Standard outcomes should be 
laboratory confirmed as influenza-associated, preferably by RT-PCR. Mild disease such as 
influenza-like illness or medically attended acute respiratory infection, and more severe 
presentations such as WHO-defined SARI are useful outcomes to measure, if laboratory 
confirmed. Measurement of VE against SARI may have more public health meaning in 
countries implementing programs for the first time, but also may present challenges such as 
smaller numbers of participants and therefore statistical power. Pooling of data from 
multiple studies with defined protocols can enhance the accuracy of VE estimates in this 
respect.
6. Conclusions and next steps
Key points of the two-day meeting encompassed discussions on a wide range of 
methodological and operational issues related to estimating the effectiveness of influenza 
vaccines. Expanded influenza vaccine production and efficacy research in tropical and 
lower-income countries demonstrate an increased focus on influenza vaccination in these 
settings, although some data gaps remain among target populations. The inherent antigenic 
drift of circulating influenza viruses also presents unique scientific questions, such as how 
antigenic match among virus strains relates to immunological protection, and optimal timing 
of vaccination of pregnant women, particularly in tropical settings with ongoing virus 
circulation. Observational studies in Europe, the US, Canada, and Australia, often using test-
negative design methodology, are benefiting from multi-site collaboration and data pooling, 
which allows for increased analytic power but also presents challenges in harmonization, 
data comparability, and long-term sustainability. Improved communication of the value of 
influenza vaccination and clear messaging on the effectiveness of different vaccine products 
in different populations are essential.
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A key next step for global influenza VE estimation is the production of a guidance document 
outlining best-practice approaches to observational approaches for VE estimation. The 
meeting concluded that this guidance document would provide researchers with standard 
case definitions and options for different methods in different settings, including choices in 
selection of controls, as well as minimum sample size for key analyses and monitoring and 
evaluation for impact assessment of vaccine programs. VE estimates from low- and middle-
income countries are especially needed, so any VE research guidance should be operational 
in these settings. Such a document could also serve to identify VE data gaps in countries 
with new introduction or expansion of vaccine recommendations. Agreement on 
methodologies can also generate new opportunities for pooling data, in order to increase the 
impact of individual efforts for quantifying the effectiveness of influenza vaccines.
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